Abstract

Warby Parker Inc. will release its fiscal first-quarter 2026 results on May 7, 2026 Pre-Market; consensus points to revenue of 239.60 million US dollars (+6.29% year over year) and adjusted EPS of 0.11 (−4.09% year over year), with investors watching trajectory in optical, contacts, and the margin impact of new product initiatives.

Market Forecast

Market models for the current quarter anticipate revenue of 239.60 million US dollars, up 6.29% year over year, with adjusted EPS at 0.11, implying a 4.09% year-over-year decline and EBIT of 12.67 million US dollars (−18.03% year over year). No explicit gross or net margin guidance is embedded in these estimates, though the setup implies continued top-line expansion alongside near-term pressure on operating profitability. The company’s core revenue engine remains optical frames and lenses, which continue to dominate the mix and set the tone for quarterly sales and gross margin. Contacts are positioned as the most promising growth contributor, supported by recurring purchase behavior; segment revenue stood at 97.15 million US dollars last quarter, with year-over-year segment growth not disclosed.

Last Quarter Review

In the prior quarter, Warby Parker Inc. reported revenue of 211.97 million US dollars (+11.19% year over year), a gross profit margin of 52.39%, GAAP net loss attributable to the company of 5.95 million US dollars, a net profit margin of −2.81%, and adjusted EPS of 0.02. Quarter-on-quarter, GAAP net profit declined by 201.34%, underscoring the sensitivity of bottom-line results to seasonal expenses and operating investments. Within the revenue mix, eyewear products were the primary contributor at 719.06 million US dollars (82.47% of mix), followed by contacts at 97.15 million US dollars (11.14%) and eye care services at 55.69 million US dollars (6.39%); segment year-over-year growth rates were not disclosed, but the concentration in core optical remains clear.

Current Quarter Outlook

Core optical business: frames and lenses will anchor revenue and gross margin

The core optical franchise—frames and prescription lenses—continues to be the defining driver of quarterly performance in both revenue and gross margin. With eyewear products comprising 82.47% of the recent revenue mix, quarter-to-quarter swings in unit volume and average order value can materially influence consolidated figures. Consensus revenue of 239.60 million US dollars (+6.29% year over year) presupposes steady throughput in stores and online, alongside manageable promotional activity. Gross margin sensitivity remains centered on product mix, lab throughput, and logistics costs. The prior quarter’s gross margin of 52.39% sets a high bar; sustaining a margin profile around that level typically requires a favorable tilt toward higher-margin optical sales relative to lower-margin categories, efficient utilization across lens labs, and stable inbound freight. Any incremental promotional cadence to support spring demand could weigh on margin, but breadth of prescription offerings and lens upgrades can offset discounts with richer baskets. Operationally, store productivity, appointment conversion for eye exams, and replenishment speed on top-selling styles are likely to matter more this quarter than macro factors, given Warby Parker Inc.’s largely controlled go-to-market model. Management’s recent cadence of product refreshes and tighter assortment curation suggests less clearance pressure, which would help preserve gross margin even if traffic normalizes after the holiday-laden Q4 period. Investors will parse commentary for order flow into proprietary lens labs and cycle times, which can be leading indicators for margin and fulfillment efficiency into the summer months.

Growth segment: contacts and eye care services deepen recurring revenue

Contacts serve as the company’s most promising add-on category for lifetime value, with 97.15 million US dollars in recent revenue contribution and a structural propensity for repeat purchase. As spring usage increases and prescriptions renew post-holidays, contacts typically provide sequential stability; the consensus EPS dip this quarter (−4.09% year over year) suggests that scale benefits from contacts may be partly offset by upfront marketing and service costs. Nevertheless, the category’s growing attachment rate can support revenue quality even as overall growth moderates. Eye exams and eye care services augment customer engagement and act as a cross-sell vector into frames, lenses, and contacts. The 55.69 million US dollars in recent eye care revenue underscores the role of services in driving multi-category conversion and data capture for personalized outreach. Exam volumes and scheduling density into late March and April are key markers for conversion into higher-value optical purchases in May and June; management’s color on exam capacity and new patient intake will help frame the extent to which services bolster near-term sales. Product innovation remains an incremental lever. On April 28, 2026, the company launched Warby Parker Sport performance eyewear in prescription and non-prescription options with a 195 US dollars starting point. This broadens the frame portfolio for active use cases and could lift average order value where customers combine performance frames with lenses or pick up contacts in the same basket. Early demand signals for Sport and the merchandising strategy around seasonal outdoor activity can influence late-quarter sell-through and mix.

Stock-price swing factors this quarter: operating leverage, product launches, and expense timing

With EBIT estimated at 12.67 million US dollars, the quarter’s stock reaction will likely hinge on operating leverage: how much of the revenue growth shows up in contribution profit after variable costs and whether fixed costs scale in line with plan. A modest miss on margin could overshadow an in-line revenue print, especially after the last quarter’s negative net margin of −2.81% and the 201.34% quarter-on-quarter decline in net profit. Conversely, evidence of accelerating conversion and stable gross margin near the low 50s could fuel a constructive reaction even if EPS lands in the mid-range of 0.11. Expense timing is a second critical variable. Marketing investment to support new product drops—such as the Sport line—and customer acquisition ahead of peak exam season may front-load costs into Q1, dampening EPS even as revenue grows. Management’s framing of branding versus performance marketing mix, customer acquisition cost trends, and retention metrics will shape how investors model expense run-rate into Q2 and the second half. Leadership and execution updates can also influence perception of the near-term earnings path. The appointment of a new chief financial officer, effective February 10, 2026, signals continued focus on financial discipline and capital allocation. Investors will look for commentary on inventory turns, working capital, and lab capacity planning as litmus tests for tighter execution. Any indication of stronger cash conversion or improved inventory efficiency could provide a counterbalance to EPS pressures from growth investments.

Analyst Opinions

The balance of recent published views skews bullish. Among six notable opinions in the January 1, 2026 to April 30, 2026 window, four were Buy ratings and two were Neutral/Hold, indicating roughly two-thirds of coverage tilts positive. The bullish cohort highlights revenue durability in optical, traction in contacts and services, and a disciplined path toward earnings quality, even as near-term EBIT and EPS face investment-related headwinds. TD Cowen’s Oliver Chen reiterated a Buy rating and raised the price target to 30.00 US dollars, citing accelerated top-line growth initiatives and product expansion. The note emphasizes the compounding effect of a broader assortment and cross-category engagement, which can smooth seasonality and enhance customer lifetime value. In the near term, Chen’s constructive stance implies that a 6.29% year-over-year revenue increase is compatible with structurally improving unit economics as scale in labs, services, and digital operations accumulates. Goldman Sachs’ Brooke Roach maintained a Buy rating with a 27.00 US dollars price target, focusing on execution across core optical and add-on categories. The firm’s constructive view suggests that merchandise newness—now including the Sport performance line—and omnichannel connectivity should support steady demand and basket size. For this print, Goldman appears most sensitive to stability in gross margin and confirmation that contacts and services are maintaining healthy repeat dynamics, which together could validate current revenue estimates even if EPS reflects ongoing investment. Piper Sandler’s Anna Andreeva kept a Buy rating and a 28.00 US dollars target, pointing to product refresh cadence and customer acquisition opportunities tied to service expansion. Piper’s framework implies that higher-frequency categories such as contacts help anchor recurring revenue, while frames and lenses benefit from new styles and lens upgrades. The firm is likely to see confirmation in an in-line to slightly better revenue trajectory as sufficient to underpin the positive thesis, provided operating expense growth is framed as deliberate and productivity-enhancing. Telsey Advisory’s Jason Strominger reaffirmed a Buy with a 24.00 US dollars target, underscoring the balance between growth investments and profitability milestones. Telsey’s stance indicates that visibility into marketing efficiency and inventory discipline could outweigh a softer EPS comparison this quarter. In other words, if management signals a clean inventory position and measured promotions, the pathway to EBIT improvement into the second half looks attainable in their model. The minority neutral-to-hold camp acknowledges healthy revenue momentum but prefers evidence of sustained margin progress before moving to a more constructive stance. However, the preponderance of Buy ratings suggests that institutional investors expect Q1 to mark continued expansion in sales, with contacts and services reinforcing durability and product innovation creating incremental upside optionality. For near-term share performance, the key checkpoints flagged across the positive camp are: confirmation of revenue near 239.60 million US dollars, gross margin resilience relative to the prior quarter’s 52.39%, and a clear articulation of expense pacing as growth investments ramp around product and services. If these are met or exceeded, the bullish majority anticipates that the stock can absorb EPS noise tied to investment timing while retaining confidence in the multi-quarter earnings trajectory.